Baseline risk as predictor of treatment benefit: three clinical meta-re-analyses.

A relationship between baseline risk and treatment effect is increasingly investigated as a possible explanation of between-study heterogeneity in clinical trial meta-analysis. An approach that is still often applied in the medical literature is to plot the estimated treatment effects against the estimated measures of risk in the control groups (as a measure of baseline risk), and to compute the ordinary weighted least squares regression line. However, it has been pointed out by several authors that this approach can be seriously flawed. The main problem is that the observed treatment effect and baseline risk measures should be viewed as estimates rather than the true values. In recent years several methods have been proposed in the statistical literature to potentially deal with the measurement errors in the estimates. In this article we propose a vague priors Bayesian solution to the problem which can be carried out using the 'Bayesian inference using Gibbs sampling' (BUGS) implementation of Markov chain Monte Carlo numerical integration techniques. Different from other proposed methods, it uses the exact rather than an approximate likelihood, while it can handle many different treatment effect measures and baseline risk measures. The method differs from a recently proposed Bayesian method in that it explicitly models the distribution of the underlying baseline risks. We apply the method to three meta-analyses published in the medical literature and compare the results with the outcomes of the other recently proposed methods. In particular we compare our approach to McIntosh's method, for which we show how it can be carried out using standard statistical software. We conclude that our proposed method offers a very general and flexible solution to the problem, which can be carried out relatively easily with existing Bayesian analysis software. A confidence band for the underlying relationship between true effect measure and baseline risk and a confidence interval for the value of the baseline risk measure for which there is no treatment effect are easily obtained by-products of our approach.

[1]  N J Nagelkerke,et al.  Variation in baseline risk as an explanation of heterogeneity in meta-analysis by S. D. Walter, Statistics in Medicine, 16, 2883-2900 (1997) , 1999, Statistics in medicine.

[2]  P. Flandre,et al.  Estimating the proportion of treatment effect explained by a surrogate marker by D. Y. Lin, T. R. Fleming and V. De Gruttola, Statistics in Medicine, 16, 1515–1527 (1997) , 1999 .

[3]  H. V. van Houwelingen,et al.  Investigating underlying risk as a source of heterogeneity in meta-analysis. , 1999, Statistics in medicine.

[4]  S D Walter,et al.  Variation in baseline risk as an explanation of heterogeneity in meta-analysis. , 1997, Statistics in medicine.

[5]  S G Thompson,et al.  Investigating underlying risk as a source of heterogeneity in meta-analysis. , 1997, Statistics in medicine.

[6]  Daniel T. Larose,et al.  Grouped random effects models for Bayesian meta-analysis. , 1997, Statistics in medicine.

[7]  R J Cook,et al.  A logistic model for trend in 2 x 2 x kappa tables with applications to meta-analyses. , 1997, Biometrics.

[8]  Douglas G Altman,et al.  The relation between treatment benefit and underlying risk in meta-analysis , 1996, BMJ.

[9]  M. McIntosh,et al.  The population risk as an explanatory variable in research synthesis of clinical trials. , 1996, Statistics in medicine.

[10]  D J Spiegelhalter,et al.  Bayesian approaches to random-effects meta-analysis: a comparative study. , 1995, Statistics in medicine.

[11]  M. Egger,et al.  Risks and benefits of treating mild hypertension: a misleading meta-analysis? , 1995, Journal of hypertension.

[12]  D E Grobbee,et al.  Does drug treatment improve survival? Reconciling the trials in mild‐to-moderate hypertension , 1995, Journal of hypertension.

[13]  P. Rothwell,et al.  Can overall results of clinical trials be applied to all patients? , 1995, The Lancet.

[14]  A. Hoes,et al.  Meta-analysis and the Hippocratic principle of primum non nocere--authors' reply. , 1995, Journal of hypertension.

[15]  S G Thompson,et al.  Systematic Review: Why sources of heterogeneity in meta-analysis should be investigated , 1994, BMJ.

[16]  R. Carroll,et al.  Measurement error, instrumental variables and corrections for attenuation with applications to meta-analyses. , 1994, Statistics in medicine.

[17]  S. Senn,et al.  IMPORTANCE OF TRENDS IN THE INTERPRETATION OF AN OVERALL ODDS RATIO IN THEMETA-ANALYSIS OF CLINICAL TRIALS. AUTHOR'S REPLY , 1994 .

[18]  H C Van Houwelingen,et al.  A bivariate approach to meta-analysis. , 1993, Statistics in medicine.

[19]  J. Collet,et al.  An Effect Model for the Assessment of Drug Benefit: Example of Antiarrhythmic Drugs in Postmyocardial Infarction Patients , 1993, Journal of cardiovascular pharmacology.

[20]  F. Song,et al.  Cholesterol lowering and mortality: the importance of considering initial level of risk. , 1993, BMJ.

[21]  F. Mosteller,et al.  A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. , 1992, JAMA.

[22]  H Kragt,et al.  Importance of trends in the interpretation of an overall odds ratio in the meta-analysis of clinical trials. , 1992, Statistics in medicine.

[23]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias , 1990, The Lancet.

[24]  K A L'Abbé,et al.  Meta-analysis in clinical research. , 1987, Annals of internal medicine.

[25]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.